OBJECTIVES: This study determined whether greater volumes of exercise were associated with greater reductions in clinical events. BACKGROUND: The HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial showed that among patients with heart failure (HF), regular exercise confers a modest reduction in the adjusted risk for all-cause mortality or hospitalization. METHODS: Patients randomized to the exercise training arm of HF-ACTION who were event-free at 3 months after randomization were included (n = 959). Median follow-up was 28.2 months. Clinical endpoints were all-cause mortality or hospitalization and cardiovascular mortality or HF hospitalization. RESULTS: A reverse J-shaped association was observed between exercise volume and adjusted clinical risk. On the basis of Cox regression, exercise volume was not a significant linear predictor but was a logarithmic predictor (p = 0.03) for all-cause mortality or hospitalization. For cardiovascular mortality or HF hospitalization, exercise volume was a significant (p = 0.001) linear and logarithmic predictor. Moderate exercise volumes of 3 to <5 metabolic equivalent (MET)-h and 5 to <7 MET-h per week were associated with reductions in subsequent risk that exceeded 30%. Exercise volume was positively associated with the change in peak oxygen uptake at 3 months (r = 0.10; p = 0.005). CONCLUSIONS: In patients with chronic systolic HF, volume of exercise is associated with the risk for clinical events, with only moderate levels (3 to 7 MET-h per week) of exercise needed to observe a clinical benefit. Although further study is warranted to confirm the relationship between volume of exercise completed and clinical events, our findings support the use of regular exercise in the management of these patients.
RCT Entities:
OBJECTIVES: This study determined whether greater volumes of exercise were associated with greater reductions in clinical events. BACKGROUND: The HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial showed that among patients with heart failure (HF), regular exercise confers a modest reduction in the adjusted risk for all-cause mortality or hospitalization. METHODS:Patients randomized to the exercise training arm of HF-ACTION who were event-free at 3 months after randomization were included (n = 959). Median follow-up was 28.2 months. Clinical endpoints were all-cause mortality or hospitalization and cardiovascular mortality or HF hospitalization. RESULTS: A reverse J-shaped association was observed between exercise volume and adjusted clinical risk. On the basis of Cox regression, exercise volume was not a significant linear predictor but was a logarithmic predictor (p = 0.03) for all-cause mortality or hospitalization. For cardiovascular mortality or HF hospitalization, exercise volume was a significant (p = 0.001) linear and logarithmic predictor. Moderate exercise volumes of 3 to <5 metabolic equivalent (MET)-h and 5 to <7 MET-h per week were associated with reductions in subsequent risk that exceeded 30%. Exercise volume was positively associated with the change in peak oxygen uptake at 3 months (r = 0.10; p = 0.005). CONCLUSIONS: In patients with chronic systolic HF, volume of exercise is associated with the risk for clinical events, with only moderate levels (3 to 7 MET-h per week) of exercise needed to observe a clinical benefit. Although further study is warranted to confirm the relationship between volume of exercise completed and clinical events, our findings support the use of regular exercise in the management of these patients.
Authors: Rod S Taylor; Allan Brown; Shah Ebrahim; Judith Jolliffe; Hussein Noorani; Karen Rees; Becky Skidmore; James A Stone; David R Thompson; Neil Oldridge Journal: Am J Med Date: 2004-05-15 Impact factor: 4.965
Authors: R Hambrecht; E Fiehn; C Weigl; S Gielen; C Hamann; R Kaiser; J Yu; V Adams; J Niebauer; G Schuler Journal: Circulation Date: 1998-12-15 Impact factor: 29.690
Authors: Fabiana Roveda; Holly R Middlekauff; Maria Urbana P B Rondon; Soraya F Reis; Márcio Souza; Luciano Nastari; Antonio Carlos P Barretto; Eduardo M Krieger; Carlos Eduardo Negrão Journal: J Am Coll Cardiol Date: 2003-09-03 Impact factor: 24.094
Authors: Stephan Gielen; Volker Adams; Sven Möbius-Winkler; Axel Linke; Sandra Erbs; Jiangtao Yu; Werner Kempf; Andreas Schubert; Gerhard Schuler; Rainer Hambrecht Journal: J Am Coll Cardiol Date: 2003-09-03 Impact factor: 24.094
Authors: S Schwarz; A Boscheri; J Christle; A Duvinage; K Esefeld; H Fricke; N Pitsch; A Pressler; M Weichenberger; M Halle Journal: Herz Date: 2016-03 Impact factor: 1.443
Authors: Robert J Mentz; Vera Bittner; Phillip J Schulte; Jerome L Fleg; Ileana L Piña; Steven J Keteyian; Gordon Moe; Anil Nigam; Ann M Swank; Anekwe E Onwuanyi; Meredith Fitz-Gerald; Andrew Kao; Stephen J Ellis; William E Kraus; David J Whellan; Christopher M O'Connor Journal: Am Heart J Date: 2013-07-12 Impact factor: 4.749
Authors: Tariq Ahmad; Mona Fiuzat; Daniel B Mark; Ben Neely; Megan Neely; William E Kraus; Dalane W Kitzman; David J Whellan; Mark Donahue; Faiez Zannad; Ileana L Piña; Kirkwood Adams; Christopher M O'Connor; G Michael Felker Journal: Am Heart J Date: 2013-11-04 Impact factor: 4.749
Authors: Lauren B Cooper; Robert J Mentz; Jie-Lena Sun; Phillip J Schulte; Jerome L Fleg; Lawton S Cooper; Ileana L Piña; Eric S Leifer; William E Kraus; David J Whellan; Steven J Keteyian; Christopher M O'Connor Journal: Circ Heart Fail Date: 2015-11 Impact factor: 8.790